This is a medicine used to treat low sodium levels in the blood. It helps the body retain more salt and water, which can raise the sodium level. It's also used to slow down the growth of cysts in people with a specific kidney disease.
Every report comes from a Lived member, sent anonymously.
Have you tried Tolvaptan for Autosomal Dominant Polycystic Kidney?
Tolvaptan is a prescription tablet sold under two brand names for two quite different purposes. Jynarque is used long term to slow the loss of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD) who are at risk of rapid progression. ADPKD is an inherited condition in which fluid-filled cysts grow in both kidneys, gradually enlarging them and reducing how well they work. Samsca is used for a short time to raise low blood sodium (hyponatremia) when it is clinically significant, generally a sodium level below 125 mEq/L, or a milder drop that causes symptoms and has not improved with fluid restriction. It is used in people who have too much water relative to sodium, including people with heart failure or SIADH (syndrome of inappropriate antidiuretic hormone), a condition in which the body holds on to too much water. Samsca is not meant for emergencies in which sodium must be raised urgently because of serious neurological symptoms, and it has not been shown to make people feel better, only to raise the sodium level. Generic tolvaptan is available for both uses. The two products have different doses, safety programs and time limits, so one is never a substitute for the other.
Vasopressin, also called antidiuretic hormone, tells the kidneys to hold on to water. It does this by attaching to V2 receptors in the kidney's collecting tubes, which opens water channels and pulls water back into the body. Tolvaptan blocks those V2 receptors. The kidneys then release more water in the urine without releasing extra sodium, a process called aquaresis. In hyponatremia, removing this extra water concentrates the blood, so the sodium level rises. In ADPKD, vasopressin also appears to drive cyst growth through a signaling molecule called cAMP inside kidney cells. By blocking vasopressin's signal, tolvaptan slows how fast cysts and kidneys enlarge, which in turn slows the decline in kidney function. It does not shrink existing cysts or cure the disease.
For ADPKD, Jynarque is taken twice a day: a larger dose on waking and a smaller dose about 8 hours later. The prescriber starts with a lower total dose and raises it, no faster than about once a week, to the highest dose the person can tolerate. If a dose is missed, skip it and take the next dose at its usual time. Because of its liver risk, Jynarque is dispensed only through a restricted safety program (a REMS, or Risk Evaluation and Mitigation Strategy) by certified specialty pharmacies, and both prescriber and patient must enroll and keep up with required blood tests. For low sodium, Samsca is taken once a day and must be started, or restarted after a break, in a hospital where sodium can be checked closely. Raising sodium too quickly can cause osmotic demyelination, a serious and sometimes permanent injury to the brain. Fluid restriction is usually paused for the first day. Samsca is not taken for more than 30 days, to limit the risk of liver injury. After stopping, people usually go back to fluid restriction and have their sodium rechecked. With either product, drink water whenever you feel thirsty, and through the day and at night if you are awake. If you cannot drink enough for any reason, such as vomiting, diarrhea or no access to water, stop the medicine and contact the prescriber right away.
The most common effects come directly from how tolvaptan works: frequent urination, large amounts of urine, getting up at night to urinate, thirst and dry mouth. In the main ADPKD trial, about 7 in 10 people on tolvaptan noticed more urination and about 6 in 10 felt more thirsty. Fatigue, dizziness, diarrhea, indigestion and reduced appetite are also more common than with a placebo. Some people adjust by planning bathroom access and timing, but these effects are the main reason people stop taking it. Losing too much water can lead to dehydration or a sodium level that climbs too high. Stop the medicine and contact the prescriber right away for dizziness, fainting, a racing or pounding heartbeat, confusion, weakness, unsteady walking or unexpected weight loss. Tolvaptan can cause serious liver injury, which has rarely led to liver failure needing a transplant. Stop taking it and contact the prescriber right away if you notice unusual tiredness, loss of appetite, nausea or vomiting, pain or discomfort in the upper right side of the belly, fever, rash, itching, dark urine, or yellowing of the skin or eyes.
Liver safety is the central warning. Jynarque carries the FDA's most serious (boxed) warning for liver injury, and blood tests of liver enzymes (ALT and AST) and bilirubin are required before starting, at 2 and 4 weeks, monthly for the first 18 months, and every 3 months after that. Catching a rise early and stopping the drug can reduce, but not remove, the risk. Tolvaptan is not used in people with significant liver disease, although uncomplicated cysts in the liver, common in ADPKD, do not rule it out. Samsca carries its own boxed warning about raising sodium too quickly and about not being used for ADPKD outside the restricted program. In people with cirrhosis, Samsca trials also saw more gastrointestinal bleeding. The liver breaks tolvaptan down through an enzyme called CYP3A. Medicines that strongly block this enzyme, such as the antifungals ketoconazole and itraconazole and the HIV medicine ritonavir, can raise tolvaptan levels several-fold and must not be combined with it. Moderate blockers require a lower Jynarque dose and should be avoided with Samsca. Grapefruit juice has a similar effect and should be avoided. Medicines that strongly speed up this enzyme can make tolvaptan less effective. Tolvaptan also counteracts desmopressin, a synthetic form of vasopressin. With Samsca, potassium is checked in people also taking blood pressure medicines called ACE inhibitors or angiotensin receptor blockers or potassium-sparing diuretics. Tolvaptan is not for people who cannot sense or respond to thirst, who are already low on fluid, who cannot pass urine, or whose urine flow is blocked, for example by an enlarged prostate. Its effects in pregnancy are not well known, so tell the prescriber about a pregnancy or plans for one. Breastfeeding is not advised during treatment.
For ADPKD, tolvaptan is a long-term treatment aimed at the future rather than at how someone feels today. In clinical trials it slowed kidney growth and the yearly fall in kidney function compared with a placebo, both in earlier and in more advanced disease, but kidney function still declined. In a 3-year trial of people with early disease, kidney volume grew about 2.8% a year with tolvaptan versus 5.5% with placebo. People will not feel the benefit directly, and it is measured over years through kidney blood tests and sometimes imaging. The heavy urination tends to stay throughout treatment, and the regular liver tests continue for as long as the medicine is taken. Some people find the trade-off worthwhile, while others stop because of the effect on daily life and sleep. For low sodium, Samsca typically raises sodium over the first days in hospital, with frequent blood tests to make sure it rises safely. It is a short-term measure. The underlying cause, such as heart failure or SIADH, still needs its own treatment, and sodium can fall again once Samsca stops.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Tolvaptan, what you've noticed, or ask the community a question.